• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Gen Fam Med . Healthcare use and RT-PCR testing during the first wave of the COVID-19 pandemic in Japan

tetano

Editor, Senior Moderator
J Gen Fam Med


. 2021 Nov 30;23(1):3-8.
doi: 10.1002/jgf2.512. eCollection 2022 Jan.
Healthcare use and RT-PCR testing during the first wave of the COVID-19 pandemic in Japan


Masaru Kurihara[SUP] 1 [/SUP], Kazuhiro Kamata[SUP] 2 [/SUP], Shun Nakahara[SUP] 1 [/SUP], Kyoko Kitazawa[SUP] 3 [/SUP], Shunzo Koizumi[SUP] 4 [/SUP], Yasuharu Tokuda[SUP] 5 [/SUP]



Affiliations

Abstract

Background: Rapid testing, tracing, and isolation among symptomatic patients are the standard for controlling the COVID-19. However, during spring 2020, Japan employed a RT-PCR test policy by using a guideline, which was used for the public to visit hospitals or clinics when they had mild symptoms for 4 days or longer ("4-day rule") among low-risk patients. It is unknown of patients' experience of healthcare use and testing during the period under the guideline. Thus, we investigated the healthcare visiting and testing among patients who developed cold-like symptoms during the period.
Methods: Our survey was conducted online in September 2020 to a nationally representative sample of adults throughout Japan. We investigated the public's understanding of the guideline. In addition, we asked their experience with healthcare use and testing if they had noticed new-onset cold-like symptoms.
Results: Of 2,137 people surveyed, 1,698 (79.5%) recognized the guidelines, but 422 people (19.7%) misunderstood. There were 144 (6.7% of 2,137 people) who developed cold-like symptoms, and many of them experienced difficulties in getting through telephone calls to a public health center, and 25 (17% of 144 people) visited healthcare institutions. Of these 25 symptomatic patients, 15 (60%) could not receive testing because of decisions by physicians (14 patients) or a local public health center (1 patient).
Conclusion: There was a low use of healthcare and testing among symptomatic patients during the first wave of the pandemic in Japan. Testing capacity should be increased to provide effective care for patients with suspected COVID-19 in Japan.

Keywords: COVID‐19; RT‐PCR test; guideline; healthcare use; novel coronavirus.
 
Back
Top Bottom